Molecular Profiles has joined a UK consortium, led by Astra Zeneca, focused on improving the pathway for developing pediatric formulations. The consortium recently received a grant from the UK’s Technology Strategy Board, to help fund a £1 million project aimed at accelerating pediatric formulation development through design and predictive science.
 
The consortium is comprised of pharmaceutical analytical development specialist Molecular Profiles, along with Pfizer, Bristol-Myers Squibb, GlaxoSmithKline and academic institutions. The pediatric formulation development project will draw on the combined expertise of the consortium members and focus on flexible dosing and providing effective taste-masking.
 
Molecular Profiles’ chief executive officer Nikin Patel said, “This collaborative project is an ambitious venture aimed at developing a strategic pathway to expedite the development of pediatric formulations, establishing the UK as a global leader in this area. Receipt of the Technology Strategy Board grant will enable us to move forward with this multi-partner project.
 
“To be involved with such credible consortium members from both large pharmaceutical companies and academia is exciting for Molecular Profiles. Our team is ready to apply our expertise to assist the consortium in achieving its collective goals,” added Dr. Patel.